MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Breast Neoplasms

Interventions

DRUG

MM-111 + Herceptin

For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV

Trial Locations (3)

Indiana University (IUPUI), Indianapolis

Huntsman Cancer Institute, Salt Lake City

Massachusetts General Hospital, Boston